Table 1.

Demographic characteristics of study samples.

Baltimore Longitudinal Study of Aging (BLSA): study sample
	Total sample, N = 29	CN, N = 8	ASY, N = 6	AD, N = 15
Age at death, mean (SD)	86.83 (9.88)	83.97 (15.06)	83.78 (6.71)	89.58 (6.99)
Age of onset, mean (SD)	–	–	–	80.88 (7.83)^a
Disease duration, mean (SD)	–	–	–	8.70 (3.89)^a
Sex, n (% female)	14 (48.28)^a	4 (50.00)	3 (50.00)	7 (46.67)^a
Race, n (% white)	27 (93.10)^a	6 (75.00)^a,b	6 (100.00)	15 (100.00)^b
APOE e4 carrier, n (%)	8 (30.77)	2 (25.00)	1 (20.00)	5 (38.46)
Statin use, n (%)	6 (20.69)^a	3 (37.50)	1 (16.67)	2 (13.33)^a
CERAD, mean (SD)	1.90 (1.14)	0.25 (0.46)^b,d	2.17 (0.41)^c,d	2.67 (0.49)^b,c
Braak, mean (SD)	4.00 (1.65)	2.63 (1.30)^b	3.50 (1.64)	4.94 (1.22)^b
Postmortem interval (hours), mean (SD)	15.48 (12.20)^a	11.38 (6.41)	13.58 (4.36)	18.64 (16.03)^a

Religious Orders Study (ROS): study sample
	Total sample, N = 71	CN, N = 22	ASY, N = 18	AD, N = 31
Age at death, mean (SD)	89.52 (7.02)	87.44 (6.75)^b	86.42 (7.65)^c	92.81 (5.45)^b,c
Age of onset, mean (SD)	–	–	–	89.13 (5.71)^a
Disease duration, mean (SD)	–	–	–	3.67 (2.94)^a
Sex, n (% female)	55 (77.46)^a	13 (59.09)^b	15 (83.33)	27 (87.10)^a,b
Race, n (% white)	71 (100.00)^a	22 (100.00)^a	18 (100.00)	31 (100.00)
APOE e4 carrier, n (%)	19 (27.54)	4 (18.18)	6 (33.33)	9 (31.03)
Statin use, n (%)	41 (57.75)^a	13 (59.09)	10 (55.56)	18 (58.06)^a
CERAD, mean (SD)	1.82 (1.15)	0.32 (0.65)^b,d	2.33 (0.49)^d	2.58 (0.50)^b
Braak, mean (SD)	3.85 (1.14)	2.91 (1.11)^b,d	3.61 (0.85)^c,d	4.65 (0.66)^b,c
Postmortem interval (hours), mean (SD)	9.48 (6.14)^a	9.59 (5.35)	10.80 (8.24)	8.67 (5.36)^a

AD Alzheimer’s disease, CN cognitively normal, ASY asymptomatic AD, Disease duration: age death—age onset.

^aP < 0.05 comparing BLSA to ROS (e.g., AD in BLSA compared to AD in ROS).

^bP < 0.05 comparing AD to CN.

^cP < 0.05 comparing AD to ASY.

^dP < 0.05 comparing ASY to CN.